Does Anthem Cover Liraglutide (Saxenda)?

What Is Liraglutide (Saxenda) and Why Does Coverage Matter?

Saxenda is the 3 mg daily injectable formulation of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved specifically for chronic weight management. It is distinct from Victoza (liraglutide 1.2 or 1.8 mg), which is approved for type 2 diabetes. Because obesity drugs have historically faced stricter formulary restrictions than diabetes drugs, understanding Anthem's specific coverage rules can save patients hundreds of dollars per month.

How Liraglutide Works

Liraglutide binds GLP-1 receptors in the hypothalamus, slowing gastric emptying and increasing satiety signals. The SCALE Obesity and Prediabetes trial (N=3,731) showed that liraglutide 3 mg produced a mean weight loss of 8.4 kg over 56 weeks compared with 2.8 kg for placebo, with 63.2% of treated participants losing at least 5% of body weight versus 27.1% with placebo [1]. The FDA cited these data when granting approval in December 2014 [2].

Why Insurers Restrict It

GLP-1 medications for weight management carry monthly list prices above $1,000, prompting payers to deploy prior authorization and step therapy to manage spending. The American Obesity Association has noted publicly that coverage denials for FDA-approved obesity pharmacotherapy remain common even when clinical guidelines support treatment [3]. Anthem's utilization management criteria reflect this industry-wide pattern.

Anthem's General Approach to Obesity Drugs

Anthem (now Elevance Health) uses a clinical criteria document called a Coverage Determination Guideline (CDG) for weight-management medications. CDGs are updated periodically and may differ between Anthem's fully insured commercial plans, self-funded employer plans, Medicaid managed care, and Medicare Advantage products. The most current CDG version should always be confirmed directly with Anthem at the time of prescribing.

Anthem's Prior Authorization Criteria for Saxenda

Prior authorization (PA) is required on virtually every Anthem plan that includes Saxenda on formulary. Submitting an incomplete PA is the single most common reason for an initial denial.

Typical Clinical Criteria

Most Anthem CDGs for liraglutide 3 mg require all of the following at the time of the PA request:

• Adult patient (age 18 or older)
• BMI of 30 or above, OR BMI of 27 or above with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Documentation of a supervised diet and exercise program attempted for a minimum of 3 to 6 months without adequate weight loss
• Prescriber is a licensed physician, nurse practitioner, or physician assistant
• No contraindicated conditions (personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, per the FDA label) [2]

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states that "pharmacotherapy for obesity should be used as an adjunct to lifestyle interventions in patients with a BMI of 30 or higher, or a BMI of 27 or higher with obesity-related comorbidities" [4]. Anthem's criteria align closely with this recommendation.

Step Therapy Requirements

Some Anthem commercial plans add a step therapy requirement. This means the patient must first try and fail a lower-cost agent, which may include:

• Phentermine/topiramate extended-release (Qsymia)
• Bupropion/naltrexone (Contrave)
• Orlistat (Alli or Xenical)

Step therapy for obesity drugs has been criticized in the medical literature. A 2021 analysis in Obesity (N=7,246 patients with obesity) found that step therapy delays of 6 months or more were associated with clinically meaningful weight regain and reduced adherence to subsequent therapy [5]. If your Anthem plan requires step therapy, your clinician can document a medical exception if prior agents are contraindicated or clinically inappropriate.

Quantity Limits and Duration of Authorization

Initial PA approvals are typically granted for 6 to 12 months. Reauthorization requires documented weight loss of at least 4% to 5% of baseline body weight, consistent with the FDA label's recommendation to discontinue Saxenda if a patient has not lost at least 4% of baseline weight after 16 weeks at the 3 mg dose [2]. Plans that do not see this response threshold may deny reauthorization even if the prescriber believes continued treatment is appropriate.

Which Anthem Plans Cover Saxenda?

Coverage status differs significantly across Anthem's product lines. Confirming coverage requires a real-time formulary check using Anthem's online drug lookup tool or a phone call to the pharmacy benefits line on the back of the member ID card.

Fully Insured Commercial Plans

Anthem's fully insured small-group and individual commercial plans generally include Saxenda on Tier 3 or Tier 4 of the formulary, subject to PA. Tier 3 typically means a higher fixed copay (often $60 to $100 per 30-day supply after deductible), while Tier 4 (non-preferred specialty) may expose patients to 25% to 40% coinsurance with no cap in some plan designs.

Self-Funded Employer Plans

Self-funded employers design their own benefit structures and may exclude obesity drugs entirely. Under the Employee Retirement Income Security Act (ERISA), self-funded plans are not required to cover weight-loss medications. If you have a self-funded Anthem plan and Saxenda is excluded, the only remedy is to request that the employer plan sponsor add the benefit.

Anthem Medicaid Plans

Anthem administers Medicaid managed care in several states. Medicaid coverage of Saxenda is state-specific. As of 2024, fewer than half of state Medicaid programs cover GLP-1 agonists for obesity as a standalone indication. Patients on Medicaid should contact their state's Medicaid drug program directly.

Anthem Medicare Advantage Plans

Medicare Part D has historically excluded drugs used "for weight loss" under 42 U.S.C. §1395w-102(e)(2)(A). The Treat and Reduce Obesity Act, if passed, would change this, but as of early 2025 that legislation has not been enacted [6]. Anthem Medicare Advantage members cannot currently receive Saxenda as a covered weight-loss medication through a standard Medicare Part D benefit, though coverage may apply if the drug is prescribed for a non-excluded indication.

How to Get Prior Authorization Approved

A well-documented PA request submitted on the first attempt is far more likely to succeed than one requiring appeals. The following approach reflects best practices described in clinical literature on PA navigation [7].

Step 1: Confirm the Current CDG

Call Anthem's provider services line (the number on the back of the patient's card) before submitting and ask for the current clinical criteria document for liraglutide 3 mg. Criteria change, and submitting against outdated criteria wastes time.

Step 2: Gather Documentation

Assemble the following before the PA is submitted:

• Current height, weight, and calculated BMI with date of measurement
• ICD-10 code E66.09 (morbid obesity) or E66.09 / E66.01 as appropriate, plus comorbidity codes
• Progress notes documenting dietary counseling and supervised exercise attempts with dates and provider names
• Labs if relevant (HbA1c, lipid panel, blood pressure readings) to document comorbidities
• A letter of medical necessity from the prescribing clinician explaining why liraglutide specifically is indicated

Step 3: Use the Correct Form and Submission Channel

Anthem accepts PA requests via Availity (electronic), fax, or phone. Electronic submission through Availity typically yields a faster determination, often within 24 to 72 hours for non-urgent requests.

Step 4: Track the PA Determination Timeline

Under the No Surprises Act and existing state prompt-pay laws, Anthem must issue a non-urgent PA determination within 3 business days for commercial plans in most states. Urgent requests must be decided within 72 hours [8].

What to Do If Anthem Denies Coverage

An initial denial is not the end of the road. Federal law and most state laws give members the right to appeal.

Internal Appeal

File an internal appeal within the timeframe specified in the denial letter, typically 180 days for commercial plans. Submit additional clinical documentation including published guidelines, the SCALE trial data [1], and a detailed letter of medical necessity. The Endocrine Society guideline language ("pharmacotherapy is recommended as an adjunct to lifestyle interventions") is particularly useful to include [4].

External Independent Review

If the internal appeal is denied, patients on fully insured commercial plans have the right to an external independent review under the Affordable Care Act. External reviewers overturn insurance denials in approximately 40% of cases involving prescription drugs, according to a 2022 JAMA Internal Medicine analysis of state external review data [9].

Expedited Appeal for Urgent Situations

If a delay in access to Saxenda would seriously jeopardize the patient's health, an expedited appeal can be filed. Expedited determinations must be issued within 72 hours under federal regulations [8].

File a State Insurance Complaint

Patients on fully insured plans can file a complaint with their state Department of Insurance if Anthem fails to follow its own utilization management procedures or violates prompt-pay or parity laws. This step is often underused but can accelerate resolution.

Cost Without Coverage: Cash Pay and Savings Programs

If coverage is denied or the plan excludes Saxenda entirely, several cost-reduction options exist.

Novo Nordisk My$avings Card

Commercially insured patients who are ineligible for government programs may qualify for the Novo Nordisk My$avings Card, which can reduce monthly out-of-pocket cost to as low as $25 per month. The card is not valid for Medicare, Medicaid, or other federal or state government-funded programs [10].

Novo Nordisk Patient Assistance Program

Uninsured or underinsured patients below certain income thresholds may qualify for free Saxenda through Novo Nordisk's patient assistance program. Applications are submitted through the NovoCare program [10].

Compounded Liraglutide

Compounded liraglutide is not FDA-approved and has not been evaluated in the same controlled trials as the branded product. The FDA has issued warnings about compounded GLP-1 formulations citing risks of dosing errors and lack of demonstrated bioequivalence [11]. HealthRX does not recommend compounded liraglutide as a substitute for Saxenda when the branded product is clinically indicated.

Therapeutic Alternatives on Formulary

If Saxenda is denied, semaglutide 2.4 mg (Wegovy) may be covered under a different tier on some Anthem plans. In the STEP-1 trial (N=1,961), once-weekly semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [12]. A prescriber can request a formulary exception or switch the prescription if Wegovy is preferred by the plan.

Understanding the Saxenda FDA Label and Its Role in PA Decisions

The FDA-approved prescribing information for Saxenda defines the clinical decision points that most PA criteria reference directly.

Approved Indications

The FDA label for Saxenda states that it is indicated "as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater in the presence of at least one weight-related comorbid condition" [2]. This language is cited verbatim in many Anthem CDGs.

Dose Escalation Schedule

Saxenda is started at 0.6 mg subcutaneously once daily and escalated by 0.6 mg each week over 4 weeks to reach the 3 mg maintenance dose. This titration schedule reduces GI side effects, which are the most common reason for discontinuation. In the SCALE trial, nausea occurred in 39.3% of liraglutide-treated participants versus 13.8% with placebo [1].

Discontinuation Criteria

The FDA label specifies that Saxenda should be discontinued if the patient has not lost at least 4% of baseline body weight after 16 weeks at the 3 mg dose. This threshold directly informs Anthem's reauthorization criteria.

Anthem Coverage for Liraglutide in Type 2 Diabetes (Victoza vs. Saxenda)

Patients with type 2 diabetes who receive liraglutide as Victoza (1.2 mg or 1.8 mg) for glycemic control face different coverage rules. Victoza is typically covered on Anthem's formulary as a diabetes medication, often at a lower tier than Saxenda. The LEADER trial (N=9,340) demonstrated that liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% versus placebo in patients with type 2 diabetes and high cardiovascular risk (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority) [13]. Anthem considers this cardiovascular outcome data when placing Victoza on formulary for diabetic indications, which is distinct from the weight-management indication evaluated for Saxenda coverage.

If a patient with type 2 diabetes also has obesity, the prescriber should clarify with Anthem whether liraglutide is being billed under the diabetes indication (Victoza) or the weight-management indication (Saxenda), as this affects which benefit and which formulary tier applies.

Key Takeaways for Prescribers and Patients

Patients asking "does Anthem cover liraglutide (Saxenda)?" need a nuanced answer. Coverage exists on many Anthem commercial plans but requires meeting specific BMI thresholds, documenting prior lifestyle interventions, and completing a prior authorization process. Self-funded employer plans and Medicare Advantage plans present the most significant coverage barriers.

Prescribers can improve PA approval rates by submitting complete documentation at the first attempt, citing current Endocrine Society and FDA criteria, and being prepared to initiate the appeal process when initial requests are denied. Patients who face persistent denials retain the right to external independent review, which reverses coverage denials at meaningful rates.

For patients who cannot obtain coverage, Novo Nordisk's savings and assistance programs may reduce financial barriers. Clinicians should document the medical rationale for liraglutide specifically, rather than relying on a generic obesity diagnosis, to support both PA submissions and any subsequent appeals.

Per the Endocrine Society's 2015 guideline: "We suggest pharmacotherapy be used as an adjunct to lifestyle intervention when the benefits of treatment outweigh the risks for the individual patient." [4] That standard provides the clearest clinical anchor for any PA request or appeal letter.